Dr. Gabriel A. Brooks
Claim this profileDartmouth Hitchcock Medical Center
Studies Colorectal Cancer
Studies Colon Cancer
9 reported clinical trials
25 drugs studied
Area of expertise
1Colorectal Cancer
Stage III
Stage IV
BRAF negative
2Colon Cancer
Stage III
Stage IV
BRAF negative
Affiliated Hospitals
Clinical Trials Gabriel A. Brooks is currently running
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
Nivolumab + Standard Treatment
for Colorectal Cancer
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
Recruiting1 award Phase 2
More about Gabriel A. Brooks
Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Gabriel A. Brooks has experience with
- Oxaliplatin
- Cetuximab
- Algorithm For Cytopenia-related Delay And Dose-reduction Of MFOLFOX Chemotherapy
- 5-FU
- FOX Dose-escalation Algorithm
- Dostarlimab
Breakdown of trials Gabriel A. Brooks has run
Colorectal Cancer
Colon Cancer
Adenocarcinoma
Appendiceal Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gabriel A. Brooks specialize in?
Gabriel A. Brooks focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Gabriel A. Brooks currently recruiting for clinical trials?
Yes, Gabriel A. Brooks is currently recruiting for 5 clinical trials in Lebanon New Hampshire. If you're interested in participating, you should apply.
Are there any treatments that Gabriel A. Brooks has studied deeply?
Yes, Gabriel A. Brooks has studied treatments such as Oxaliplatin, Cetuximab, Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy.
What is the best way to schedule an appointment with Gabriel A. Brooks?
Apply for one of the trials that Gabriel A. Brooks is conducting.
What is the office address of Gabriel A. Brooks?
The office of Gabriel A. Brooks is located at: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756 United States. This is the address for their practice at the Dartmouth Hitchcock Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.